DOMOFENOGENE ZALFAPARVOVEC
UNII PN77BRS6J9

Substance Identification & Data

This profile provides standardized clinical and technical data for Domofenogene Zalfaparvovec, uniquely identified by the FDA Unique Ingredient Identifier (UNII) PN77BRS6J9.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2382896-04-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

PN77BRS6J9

CAS Registry Number

2382896-04-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

DOMOFENOGENE ZALFAPARVOVEC

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C184853

National Cancer Institute reference terminology for clinical and research data.

INN ID

11598

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Domofenogene Zalfaparvovec. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

DOMOFENOGENE ZALFAPARVOVEC

Common Names & Synonyms

BMN 307 (AN AAV5-PHENYLALANINE HYDROXYLASE (PAH) GENE THERAPY)

BMN-307

DNA (RECOMBINANT REPLICATION-DEFICIENT ADENO-ASSOCIATED VIRUS 5 VECTOR BMN 307 HUMAN LIVER-SPECIFIC TRANSCRIPTION REGULATORY ELEMENT PLUS HUMAN PHENYLALANINE 4-HYDROXYLASE CODON-OPTIMIZED GENE HPAH PLUS ADENO-ASSOCIATED VIRUS 2 INVERTED TERMINAL REPEAT FLANKS)

DOMOFENOGENE ZALFAPARVOVEC [INN]

RECOMBINANT, REPLICATION-INCOMPETENT ADENOASSOCIATED VIRUS SEROTYPE 5 (AAV5) VECTOR ENCODING CODON-OPTIMIZED HUMAN PHENYLALANINE HYDROXYLASE (HPAH) UNDER CONTROL OF A LIVER-SELECTIVE TRANSCRIPTION REGULATORY ELEMENT (TRE), CONSISTING OF THE APOLIPOPROTEIN E ENHANCER AND THE HUMAN ALPHA-1 ANTI-TRYPSIN PROMOTER, A HUMAN ALPHA-1 ANTI-TRYPSIN/HUMAN BETA-GLOBIN HYBRID INTRON AND TERMINATED BY THE BOVINE GROWTH HORMONE POLYADENYLATION SEQUENCE, FLANKED BY AAV2 INVERTED TERMINAL REPEATS (ITRS)

External Clinical & Regulatory Resources

Previous UNIIPN6XH75UNP

Next UNIIPN7H2ZWL3L